154 related articles for article (PubMed ID: 26253838)
21. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.
Haapasalo JA; Nordfors KM; Hilvo M; Rantala IJ; Soini Y; Parkkila AK; Pastoreková S; Pastorek J; Parkkila SM; Haapasalo HK
Clin Cancer Res; 2006 Jan; 12(2):473-7. PubMed ID: 16428489
[TBL] [Abstract][Full Text] [Related]
22. Expression of EGFR in Paired New and Recurrent Glioblastomas.
Cioca A; Olteanu EG; Gisca MD; Morosanu CO; Marin I; Florian IS
Asian Pac J Cancer Prev; 2016; 17(9):4205-4208. PubMed ID: 27797218
[TBL] [Abstract][Full Text] [Related]
23. Prognostic relevance of p53 protein expression in glioblastoma.
Birner P; Piribauer M; Fischer I; Gatterbauer B; Marosi C; Ungersböck K; Rössler K; Budka H; Hainfellner JA
Oncol Rep; 2002; 9(4):703-7. PubMed ID: 12066196
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of annexin VII expression in glioblastomas multiforme in humans.
Hung KS; Howng SL
J Neurosurg; 2003 Nov; 99(5):886-92. PubMed ID: 14609169
[TBL] [Abstract][Full Text] [Related]
25. Expression of cytokeratins in glioblastoma multiforme.
Terada T
Pathol Oncol Res; 2015 Jul; 21(3):817-9. PubMed ID: 25633990
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Shono T; Tofilon PJ; Bruner JM; Owolabi O; Lang FF
Cancer Res; 2001 Jun; 61(11):4375-81. PubMed ID: 11389063
[TBL] [Abstract][Full Text] [Related]
27. Expression of p53 and p21 in primary glioblastomas.
Gross MW; Kraus A; Nashwan K; Mennel HD; Engenhart-Cabillic R; Schlegel J
Strahlenther Onkol; 2005 Mar; 181(3):164-71. PubMed ID: 15756520
[TBL] [Abstract][Full Text] [Related]
28. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma.
Hu TH; Huang CC; Lin PR; Chang HW; Ger LP; Lin YW; Changchien CS; Lee CM; Tai MH
Cancer; 2003 Apr; 97(8):1929-40. PubMed ID: 12673720
[TBL] [Abstract][Full Text] [Related]
29. Role of Asparagine Endopeptidase in Mediating Wild-Type p53 Inactivation of Glioblastoma.
Lin Y; Liao K; Miao Y; Qian Z; Fang Z; Yang X; Nie Q; Jiang G; Liu J; Yu Y; Wan J; Zhang X; Hu Y; Jiang J; Qiu Y
J Natl Cancer Inst; 2020 Apr; 112(4):343-355. PubMed ID: 31400201
[TBL] [Abstract][Full Text] [Related]
30. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
31. Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.
Liang C; Guo E; Lu S; Wang S; Kang C; Chang L; Liu L; Zhang G; Wu Z; Zhao Z; Ma S; Wang L; Jiao BH
Brain Res; 2012 Mar; 1444():65-75. PubMed ID: 22325093
[TBL] [Abstract][Full Text] [Related]
32. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines.
Amoureux MC; Coulibaly B; Chinot O; Loundou A; Metellus P; Rougon G; Figarella-Branger D
BMC Cancer; 2010 Mar; 10():91. PubMed ID: 20219118
[TBL] [Abstract][Full Text] [Related]
33. APNG as a prognostic marker in patients with glioblastoma.
Fosmark S; Hellwege S; Dahlrot RH; Jensen KL; Derand H; Lohse J; Sørensen MD; Hansen S; Kristensen BW
PLoS One; 2017; 12(6):e0178693. PubMed ID: 28662073
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Sipayya V; Sharma I; Sharma KC; Singh A
J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
[TBL] [Abstract][Full Text] [Related]
35. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma.
Kruthika BS; Sugur H; Nandaki K; Arimappamagan A; Paturu K; Santosh V
J Clin Pathol; 2019 Oct; 72(10):677-681. PubMed ID: 31270134
[TBL] [Abstract][Full Text] [Related]
36. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
Simmons ML; Lamborn KR; Takahashi M; Chen P; Israel MA; Berger MS; Godfrey T; Nigro J; Prados M; Chang S; Barker FG; Aldape K
Cancer Res; 2001 Feb; 61(3):1122-8. PubMed ID: 11221842
[TBL] [Abstract][Full Text] [Related]
37. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
38. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
39. DJ-1 expression in glioblastomas shows positive correlation with p53 expression and negative correlation with epidermal growth factor receptor amplification.
Hinkle DA; Mullett SJ; Gabris BE; Hamilton RL
Neuropathology; 2011 Feb; 31(1):29-37. PubMed ID: 20497343
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
